{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:27:37Z","timestamp":1783024057691,"version":"3.54.6"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>\n                    We present the case of a 60-year-old woman with metastatic breast cancer who underwent\n                    <jats:sup>18<\/jats:sup>\n                    F-FDG PET\/CT for treatment response assessment. Beyond oncologic findings, the scan revealed abnormal gastric retention, gallbladder, colonic, and renal uptake patterns suggestive of Semaglutide-induced gastroparesis, cholecystitis, colitis, and possible acute kidney injury secondary to dehydration. Suspicions were confirmed by clinical evaluation. Symptoms resolved after supportive therapy and withholding of semaglutide. To our knowledge, this is the first report of multi-organ side effects seen on\n                    <jats:sup>18<\/jats:sup>\n                    F-FDG PET\/CT following a single semaglutide dose administration, emphasizing the need for nuclear medicine physicians to recognize glucagon-like peptide-1 receptor agonist medication\u2013related side effects and their imaging manifestations.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006360","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T19:01:18Z","timestamp":1770404478000},"page":"e732-e733","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["18F-FDG PET\/CT Five Days Post First Administration of Semaglutide"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6932-2276","authenticated-orcid":false,"given":"Elizabeth Katherine Anna","family":"Triumbari","sequence":"first","affiliation":[{"name":"Nuclear Medicine Unit - Medipass Erg\u00e9a Group, Fondazione Policlinico Universitario Campus Bio-Medico"},{"name":"Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Lorusso","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit - Medipass Erg\u00e9a Group, Fondazione Policlinico Universitario Campus Bio-Medico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiammetta","family":"Cirillo","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit - Medipass Erg\u00e9a Group, Fondazione Policlinico Universitario Campus Bio-Medico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"D\u2019Orso","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit - Medipass Erg\u00e9a Group, Fondazione Policlinico Universitario Campus Bio-Medico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Lolli","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit - Medipass Erg\u00e9a Group, Fondazione Policlinico Universitario Campus Bio-Medico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"De Rosa","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit - Medipass Erg\u00e9a Group, Fondazione Policlinico Universitario Campus Bio-Medico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaela","family":"Di Carmine","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit - Medipass Erg\u00e9a Group, Fondazione Policlinico Universitario Campus Bio-Medico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido Maria","family":"Meduri","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit - Medipass Erg\u00e9a Group, Fondazione Policlinico Universitario Campus Bio-Medico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"R1-20260702","first-page":"e52564","article-title":"Tendency of semaglutide to induce gastroparesis: a case report","volume":"16","author":"Chaudhry","year":"2024","journal-title":"Cureus"},{"key":"R2-20260702","first-page":"e91679","article-title":"Unmasking semaglutide-induced gastroparesis: the dangers of rapid dose escalation in a diabetic patient","volume":"17","author":"Singhal","year":"2025","journal-title":"Cureus"},{"key":"R3-20260702","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/s41591-025-03542-9","article-title":"Author correction: mapping the effectiveness and risks of glp-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat Med"},{"key":"R4-20260702","doi-asserted-by":"crossref","first-page":"e001704","DOI":"10.1136\/bmjgast-2024-001704","article-title":"Comparing the risk of gastroparesis following different modalities for treating obesity: semaglutide versus bupropion-naltrexone versus sleeve gastrectomy - a retrospective cohort study","volume":"12","author":"Aneke-Nash","year":"2025","journal-title":"BMJ Open Gastroenterol"},{"key":"R5-20260702","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern Med"},{"key":"R7-20260702","doi-asserted-by":"crossref","first-page":"e436","DOI":"10.1097\/RLU.0000000000005318","article-title":"FDG PET in a patient on a GLP-1 agonist\/insulin secretagogue","volume":"49","author":"Oldan","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R8-20260702","doi-asserted-by":"crossref","first-page":"154167","DOI":"10.1016\/j.metabol.2020.154167","article-title":"Twelve weeks of exenatide treatment increases [18F]fluorodeoxyglucose uptake by brown adipose tissue without affecting oxidative resting energy expenditure in nondiabetic males","volume":"106","author":"Janssen","year":"2020","journal-title":"Metabolism"},{"key":"R9-20260702","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/lary.31815","article-title":"Brown adipose tissue mimicking head and neck cancer on PET scan in a patient on GLP-1 drug","volume":"135","author":"Harrison","year":"2025","journal-title":"Laryngoscope"},{"key":"R10-20260702","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s13063-025-09045-9","article-title":"Effect of tirzepatide-induced weight loss on adipose tissue in obesity: rationale and design of the randomized placebo-controlled Tirzepatide Brown and Beige Adipose Tissue Activation (TABFAT) trial","volume":"26","author":"Herman","year":"2025","journal-title":"Trials"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006360","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:10:38Z","timestamp":1783023038000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006360"}},"subtitle":["Side Effects in One Shot"],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":9,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006360","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"2025-11-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}